408 related articles for article (PubMed ID: 20428688)
1. In vitro and in vivo experimental models for drug screening and development for Chagas disease.
Romanha AJ; Castro SL; Soeiro Mde N; Lannes-Vieira J; Ribeiro I; Talvani A; Bourdin B; Blum B; Olivieri B; Zani C; Spadafora C; Chiari E; Chatelain E; Chaves G; Calzada JE; Bustamante JM; Freitas-Junior LH; Romero LI; Bahia MT; Lotrowska M; Soares M; Andrade SG; Armstrong T; Degrave W; Andrade Zde A
Mem Inst Oswaldo Cruz; 2010 Mar; 105(2):233-8. PubMed ID: 20428688
[TBL] [Abstract][Full Text] [Related]
2. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
[TBL] [Abstract][Full Text] [Related]
4. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo trypanocidal activity of a benzofuroxan derivative against Trypanosoma cruzi.
Dos Santos Petry L; Pillar Mayer JC; de Giacommeti M; Teixeira de Oliveira D; Razia Garzon L; Martiele Engelmann A; Magalhães de Matos AFI; Dellaméa Baldissera M; Dornelles L; Melazzo de Andrade C; Gonzalez Monteiro S
Exp Parasitol; 2021; 226-227():108125. PubMed ID: 34129877
[TBL] [Abstract][Full Text] [Related]
6. The anticancer drug tamoxifen is active against Trypanosoma cruzi in vitro but ineffective in the treatment of the acute phase of Chagas disease in mice.
Miguel DC; Ferraz ML; Alves Rde O; Yokoyama-Yasunaka JK; Torrecilhas AC; Romanha AJ; Uliana SR
Mem Inst Oswaldo Cruz; 2010 Nov; 105(7):945-8. PubMed ID: 21120371
[TBL] [Abstract][Full Text] [Related]
7. Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.
Guedes-da-Silva FH; Batista DG; da Silva CF; Meuser MB; Simões-Silva MR; de Araújo JS; Ferreira CG; Moreira OC; Britto C; Lepesheva GI; Soeiro Mde N
Antimicrob Agents Chemother; 2015 Dec; 59(12):7564-70. PubMed ID: 26416857
[TBL] [Abstract][Full Text] [Related]
8. Translational challenges of animal models in Chagas disease drug development: a review.
Chatelain E; Konar N
Drug Des Devel Ther; 2015; 9():4807-23. PubMed ID: 26316715
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of the chloroaryl-substituted imidazole viniconazole against Trypanosoma cruzi.
Silva CF; Batista Dda G; Batista MM; Lionel J; Hammer ER; Brun R; Soeiro Mde N
Parasitology; 2014 Mar; 141(3):367-73. PubMed ID: 24553079
[TBL] [Abstract][Full Text] [Related]
10. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
[TBL] [Abstract][Full Text] [Related]
11. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological in vitro and in vivo Evaluation of 2-(5-Nitroindazol-1-yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease.
Martín-Escolano R; Aguilera-Venegas B; Marín C; Martín-Montes Á; Martín-Escolano J; Medina-Carmona E; Arán VJ; Sánchez-Moreno M
ChemMedChem; 2018 Oct; 13(19):2104-2118. PubMed ID: 30098232
[TBL] [Abstract][Full Text] [Related]
13. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
14. Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies.
Soeiro Mde N; Dantas AP; Daliry A; Silva CF; Batista DG; de Souza EM; Oliveira GM; Salomão K; Batista MM; Pacheco MG; Silva PB; Santa-Rita RM; Barreto RF; Boykin DW; Castro SL
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():301-10. PubMed ID: 19753489
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
16. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
17. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
18. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
[TBL] [Abstract][Full Text] [Related]
19. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
20. Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease.
García MC; Ponce NE; Sanmarco LM; Manzo RH; Jimenez-Kairuz AF; Aoki MP
Antimicrob Agents Chemother; 2016 Jun; 60(6):3700-8. PubMed ID: 27067322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
